Intravoxel incoherent motion (IVIM) for response assessment in patients with osteosarcoma undergoing neoadjuvant chemotherapy. 2019

Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi, India.

OBJECTIVE To explore the role of quantitative Intravoxel incoherent motion (IVIM) parameters and their histogram analysis in characterizing changes in Osteosarcoma receiving neoadjuvant chemotherapy (NACT) and evaluating therapeutic response. METHODS Forty patients (N = 40; Male:Female = 30:10; Age = 17.7 ± 5.9years; Metastatic:localized = 17:23) with histologically confirmed Osteosarcoma treated with 3-cycles of NACT were analyzed prospectively. All patients underwent Diffusion weighted imaging (DWI) with 11 b-values (0-800 s/mm2) using 1.5 T MRI scanner at pre-treatment (t0), after 1-cycle (t1) and after 3-cycles (t2) of NACT. Non-invasive response evaluation of NACT was performed using RECIST1.1 criteria. Apparent-diffusion-coefficient (ADC) and IVIM parameters - Diffusion-coefficient (D), Perfusion-coefficient (D*) & Perfusion-fraction (f) and their relative percentage changes from time-point t0-t1 (Δ2) and t0-t2 (Δ2) were evaluated and histogram analysis was performed at three time-points and compared with respect to RECIST1.1 scores. RESULTS Using RECIST1.1 criteria, 11 (27.5%), 21 (52.5%) and 8 (20%) patients were in Partial-responder (PR), Stable-disease (SD) and Progressive-disease (PD) groups respectively. Pre-NACT (t0), average ADC, D,D*&f in tumor volume were 1.36 ± 0.33 × 10-3 mm2/s, 1.3 ± 0.3 × 10-3 mm2/s, 28.44 ± 10.34 × 10-3 mm2/s & 13.95 ± 2.83% respectively. Using ANOVA test, during NACT (t1, t2), D*-variance (p = 0.038, 0.003) and f-skewness (p = 0.03, 0.03) and at t2, D*-entropy (p = 0.001) and f-entropy (p = 0.002) and their Δ2 changes (p = 0.001, 0.003) were statistically significant among response groups. At t1, D*-variance and f-skewness jointly showed AUC = 0.77 & 0.74 in classifying PR (Sensitivity = 73%; Specificity = 70%) and SD (Sensitivity = 74; Specificity = 75%) groups respectively in patient cohort. Δ1 & Δ2 changes of D*-mean, D*-variance, D*-entropy and f-entropy correlated well (0.5-0.6) with tumor-diameter and tumor-volume changes. CONCLUSIONS Quantitative IVIM parameters, especially D* &f and their histogram analysis were informative and can be used as noninvasive surrogate markers for early response assessment during the course of NACT in Osteosarcoma.

UI MeSH Term Description Entries
D008297 Male Males
D009038 Motion Physical motion, i.e., a change in position of a body or subject as a result of an external force. It is distinguished from MOVEMENT, a process resulting from biological activity. Motions
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
January 2017, European journal of radiology open,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
May 2023, European journal of radiology,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
July 2012, Journal of magnetic resonance imaging : JMRI,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
April 2022, Journal of personalized medicine,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
December 2018, Journal of magnetic resonance imaging : JMRI,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
January 1987, Journal of neuroradiology = Journal de neuroradiologie,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
March 2024, Diagnostics (Basel, Switzerland),
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
May 2018, Magnetic resonance imaging,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
March 2014, Journal of magnetic resonance imaging : JMRI,
Esha Baidya Kayal, and Devasenathipathy Kandasamy, and Kedar Khare, and Sameer Bakhshi, and Raju Sharma, and Amit Mehndiratta
January 2021, European radiology,
Copied contents to your clipboard!